2022

1. Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (Annals of Hematology, (2022), 101, 10, (2231-2239), 10.1007/s00277-022-04963-z)

   Annals of Hematology

2. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

   Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

3. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

   Cancer, Vol. 128, Núm. 13, pp. 2441-2448